News Column

Shire expects strong growth

February 14, 2014


PHARMACEUTICAL group Shire's strong growth is set to continue this year, the company said yesterday, after demand for its rare disease drugs helped it report better than expected fourth-quarter profits.

Its shares hit a record high during the day, yet eased back to close roughly flat, at 3,142p.

The company also said finance chief Graham Hetherington would step down on 1 March, with the group's financial controller James Bowling taking over on an interim basis.

Shire, which makes attention deficit hyperactivity disorder drug Vyvanse, posted a 36 per cent rise in fourth-quarter earnings per American Depositary Share of $2.26 on a non-GAAP basis, on revenue up 12 per cent at $1.33bn (799.66m).

For more stories on investments and markets, please see HispanicBusiness' Finance Channel

Source: City A.M. (UK)

Story Tools